IL-23 inhibitors for Plaque Psoriasis Treatment

Dermatology experts provide an overview of tildrakizumab, guselkumab, and risankizumab, agents approved for patients with plaque psoriasis.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.